

Title (en)
CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS

Title (de)
KRISTALLINE FORMEN VON RAPAMYCINANALOGA

Title (fr)
FORMES CRISTALLINES D'ANALOGUES DE LA RAPAMYCINE

Publication
EP 2051984 A1 20090429 (EN)

Application
EP 07799771 A 20070724

Priority

- US 2007074159 W 20070724
- US 82031706 P 20060725
- US 78180407 A 20070723
- US 78180707 A 20070723

Abstract (en)
[origin: WO2008014222A1] A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula (I), which is optionally a prodrug, salt, derivative, or combination thereof: Formula (I)

IPC 8 full level
C07D 498/18 (2006.01); **A61K 31/395** (2006.01); **A61K 31/4353** (2006.01); **A61P 37/06** (2006.01)

CPC (source: EP KR)
A61P 1/02 (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/00** (2017.12 - EP); **A61P 5/14** (2017.12 - EP); **A61P 5/40** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/14** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 11/08** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 17/08** (2017.12 - EP); **A61P 17/14** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 27/12** (2017.12 - EP); **A61P 27/16** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 31/10** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 39/02** (2017.12 - EP); **A61P 39/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 498/18** (2013.01 - EP KR); **C07B 2200/13** (2013.01 - KR)

Citation (search report)
See references of WO 2008014222A1

Citation (examination)

- WO 2006060616 A1 20060608 - SAG TEVA GYOGYSZERGYAR ZARTKOE [HU], et al
- WO 2006023627 A1 20060302 - WYETH CORP [US], et al

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA HR MK RS

DOCDB simple family (publication)
WO 2008014222 A1 20080131; AU 2007276837 A1 20080131; AU 2007276837 B2 20130207; BR PI0714945 A2 20130521; BR PI0714945 B1 20201110; BR PI0714945 B8 20210525; CA 2658896 A1 20080131; EP 2051984 A1 20090429; EP 2407471 A2 20120118; EP 2407471 A3 20120620; IL 196706 A0 20091118; JP 2010500286 A 20100107; KR 20090035716 A 20090410; MX 2009001067 A 20090617; NZ 574654 A 20120330

DOCDB simple family (application)
US 2007074159 W 20070724; AU 2007276837 A 20070724; BR PI0714945 A 20070724; CA 2658896 A 20070724; EP 07799771 A 20070724; EP 11183446 A 20070724; IL 19670609 A 20090125; JP 2009521936 A 20070724; KR 20097003955 A 20090225; MX 2009001067 A 20070724; NZ 57465407 A 20070724